Overexpression of the structural maintenance of chromosome 4 protein is associated with tumor de-differentiation, advanced stage and vascular invasion of primary liver cancer

Zhou,Bo; Yuan,Tao; Liu,Menggang; Liu,Hongming; Xie,Jun; Shen,Yanbin; Chen,Ping

doi:10.3892/or.2012.1929

Overexpression of the structural maintenance of chromosome 4 protein is associated with tumor de-differentiation, advanced stage and vascular invasion of primary liver cancer

Authors:
- Bo Zhou
- Tao Yuan
- Menggang Liu
- Hongming Liu
- Jun Xie
- Yanbin Shen
- Ping Chen
View Affiliations

Affiliations: Department of Hepatobiliary Surgery Daping Hospital and Research Institute of Surgery, The Third Military Medical University, Chongqing, P.R. China
Published online on: July 24, 2012 https://doi.org/10.3892/or.2012.1929
Pages: 1263-1268

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Structural maintenance of chromosome 4 (SMC4) is associated with tumorigenesis. The present study aimed at detecting SMC4 expression in primary liver cancer and its association with clinicopathological patient data. A total of 72 primary liver cancer tissues and 6 liver cell lines were assessed for expression of SMC4 mRNA and protein with qRT-PCR, western blotting and immunohistochemistry, respectively. SMC4 siRNAs were constructed to knockdown SMC4 expression, and phenotypic changes of hepatocellular carcinoma (HCC) cells were analyzed using flow cytometry and cell viability assays. The data showed that SMC4 mRNA and protein were highly expressed in HCC tissues compared to the normal tissues. Immunohistochemical analysis revealed that 52 of 72 (72.2%) paraffin-embedded primary liver cancer tissues displayed strong cytoplasmic staining of SMC4 protein, whereas only 6 (8.3%) normal liver tissues showed immunostaining of SMC4. Statistical analysis showed that SMC4 expression was significantly associated with tumor size, de-differentiation, advanced stages and vascular invasion of the primary liver cancers. Moreover, knockdown of SMC4 expression reduced HCC cell proliferation. These data demonstrated that expression of SMC4 protein may be useful for the early detection and prediction of primary liver cancer progression.

View Figures

View References

1	El-Serag HB and Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
2	Ozenne V, Bouattour M, Goutté N, et al: Prospective evaluation of the management of hepatocellular carcinoma in the elderly. Dig Liver Dis. 43:1001–1005. 2011. View Article : Google Scholar : PubMed/NCBI
3	Lau WY and Lai EC: Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int. 7:237–257. 2008.PubMed/NCBI
4	Hawkins MA and Dawson LA: Radiation therapy for hepatocellular carcinoma from palliation to cure. Clin Cancer Res. 106:1653–1661. 2006.PubMed/NCBI
5	Takayama T: Surgical treatment for hepatocellular carcinoma. Jpn J Clin Oncol. 41:447–454. 2011. View Article : Google Scholar : PubMed/NCBI
6	Cha CH, Saif MW, Yamane BH and Weber SM: Hepatocellular carcinoma: current management. Curr Probl Surg. 47:10–67. 2010. View Article : Google Scholar : PubMed/NCBI
7	Ma S, Jiao B, Liu X, et al: Approach to radiation therapy in hepatocellular carcinoma. Cancer Treat Rev. 36:157–163. 2010. View Article : Google Scholar : PubMed/NCBI
8	Wertheim JA, Petrowsky H and Saab S: Major challenges limiting liver transplantation in the United States. Am J Transplant. 11:1773–1784. 2011. View Article : Google Scholar : PubMed/NCBI
9	Wiggermann P, Jung EM and Stroszczynski C: Radiofrequency ablation is a technique finished? Radiologe. 52:9–14. 2012.PubMed/NCBI
10	Liapi E and Geschwind JF: Medium-sized HCC: achieving effective local tumor control with combined chemoebolization and radiofrequency ablation. Ann Surg Oncol. 18:1527–1528. 2011. View Article : Google Scholar : PubMed/NCBI
11	Smerdou C, Menne S, Hernandez-Alcoceba R and Gonzalez-Aseguinolaza G: Gene therapy for HCV/HBV-induced hepatocellular carcinoma. Curr Opin Investig Drugs. 11:1368–1377. 2010.PubMed/NCBI
12	Truty MJ and Vauthey JN: Surgical resection of high-risk hepatocellular carcinoma: patient selection, preoperative considerations, and operative technique. Ann Surg Oncol. 17:1219–1225. 2010. View Article : Google Scholar
13	Abelev GI, Perova SD, Khramkova NI, Postnikova ZA and Irlin IS: Production of embryonal alpha-globulin by transplantable mouse hepatomas. Transplantation. 1:174–180. 1963. View Article : Google Scholar : PubMed/NCBI
14	Lok AS, Sterling RK, Everhart JE, et al: Des-γ-carboxy prothrombin and α-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 138:493–502. 2010.
15	Giardina MG, Matarazzo M, Varriale A, Morante R, Napoli A and Martino R: Serum alpha-L-fucosidase: a useful marker in the diagnosis of hepatocellular carcinoma. Cancer. 70:1044–1048. 1992. View Article : Google Scholar : PubMed/NCBI
16	Ishizuka H, Nakayama T, Matsuoka S, et al: Prediction of the development of hepato-cellular carcinoma in patients with liver cirrhosis by the serial determinations of serum alpha-L-fucosidase activity. Intern Med. 38:927–931. 1999. View Article : Google Scholar : PubMed/NCBI
17	Zhu ZW, Friess H, Wang L, et al: Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut. 48:558–564. 2001. View Article : Google Scholar : PubMed/NCBI
18	Allegretta M and Filmus J: Therapeutic potential of targeting glypican-3 in hepatocellular carcinoma. Anticancer Agents Med Chem. 11:543–548. 2011. View Article : Google Scholar : PubMed/NCBI
19	Oka H, Tamori A, Kuroki T, Kobayashi K and Yamamoto S: Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology. 19:61–66. 1994. View Article : Google Scholar : PubMed/NCBI
20	Ishii M, Gama H, Chida N, et al: Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. Am J Gastroenterol. 95:1036–1040. 2000.
21	Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ and Lok AS: Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology. 37:1114–1121. 2003. View Article : Google Scholar
22	Gambarin-Gelwan M, Wolf DC, Shapiro R, Schwartz ME and Min AD: Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation. Am J Gastroenterol. 95:1535–1538. 2000. View Article : Google Scholar
23	Trevisani F, D’Intino PE, Morselli-Labate AM, et al: Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol. 34:570–575. 2001. View Article : Google Scholar : PubMed/NCBI
24	Toyoda H, Kumada T, Kiriyama S, et al: Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol. 4:111–117. 2006. View Article : Google Scholar : PubMed/NCBI
25	Nakamura S, Nouso K, Sakaguchi K, et al: Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol. 101:2038–2043. 2006. View Article : Google Scholar : PubMed/NCBI
26	Uto H, Kanmura S, Takami Y and Tsubouchi H: Clinical proteomics for liver disease: a promising approach for discovery of novel biomarkers. Proteome Sci. 8:702010. View Article : Google Scholar : PubMed/NCBI
27	Sherman M: Alphafetoprotein: an obituary. J Hepatol. 34:603–605. 2001. View Article : Google Scholar
28	Losada A and Hirano T: Dynamic molecular linkers of the genome: the first decade of SMC proteins. Genes Dev. 19:1269–1287. 2005. View Article : Google Scholar : PubMed/NCBI
29	Lu KH, Patterson AP and Wang L: Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res. 10:3291–3300. 2004. View Article : Google Scholar : PubMed/NCBI
30	Kulawiec M, Safina A, Desouki MM, Still I, Matsui S, Bakin A and Singh KK: Tumorigenic transformation of human breast epithelial cells induced by mitochondrial DNA depletion. Cancer Biol Ther. 7:1732–1743. 2008. View Article : Google Scholar : PubMed/NCBI
31	Li J, Zhang N, Song LB, et al: Astrocyte elevated gene-1 is a novel prognostic marker for breast cancer progression and overall patient survival. Clin Cancer Res. 14:3319–3326. 2008. View Article : Google Scholar : PubMed/NCBI
32	Freeman L, Aragon-Alcaide L and Strunnikov A: The condensin complex governs chromosome condensation and mitotic transmission of rDNA. J Cell Biol1. 49:811–824. 2000. View Article : Google Scholar : PubMed/NCBI
33	Yu L, Peña Castillo L, Mnaimneh S, Hughes TR and Brown GW: A survey of essential gene function in the yeast cell division cycle. Mol Biol Cell1. 7:4736–4747. 2006. View Article : Google Scholar : PubMed/NCBI
34	Wang Y, Klijn JG, Zhang Y, et al: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 365:671–679. 2005. View Article : Google Scholar : PubMed/NCBI